Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | BAX | Q07812 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | TSPO | P30536 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607458 | 0.86 | RAD52 (0.66) | RAD52MEN1KMT2ABAXMAPT | |
| SCHEMBL607028 | 0.81 | MEN1 (0.76) | RAD52MEN1KMT2ABAXMAPT | |
| SCHEMBL609692 | 0.81 | MEN1 (0.41) | RAD52MEN1KMT2AMAPTTSPO | |
| SCHEMBL6363590 | 0.78 | MAPT (0.61) | RAD52MEN1KMT2ABAXMAPT | |
| SCHEMBL607745 | 0.78 | BAX (0.72) | RAD52MEN1KMT2ABAXMAPT | |
| SCHEMBL5024320 | 0.78 | BAX (0.72) | RAD52MEN1KMT2ABAXMAPT | |
| SCHEMBL29992291 | 0.78 | BAX (0.72) | RAD52MEN1KMT2ABAXMAPT | |
| SCHEMBL29398838 | 0.78 | BAX (0.72) | RAD52MEN1KMT2ABAXMAPT | |
| SCHEMBL5024339 | 0.78 | BAX (0.72) | RAD52MEN1KMT2ABAXMAPT | |
| SCHEMBL608957 | 0.77 | CCR1 (0.47) | RAD52MEN1KMT2AMAPTHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410110-B2 | 9-(piperazinylalkyl) carbazoles as Bax-modulators | MERCK SERONO SA (CH) | 2013-04-02 | — | — | US | claimed |
| US-20120040933-A1 | 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2012-02-16 | — | — | US | claimed |
| EP-1237887-B1 | 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS | SERONO LAB (CH) | 2008-06-04 | — | — | EP | claimed |
| US-8410110-B2 | 9-(piperazinylalkyl) carbazoles as Bax-modulators | MERCK SERONO SA (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120040933-A1 | 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2012-02-16 | — | — | US | disclosed |
| US-8053436-B1 | 9-(piperazinylalkyl) carbazoles as bax-modulators | MERCK SERONO SA (CH) | 2011-11-08 | — | — | US | disclosed |
| EP-1237887-B1 | 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS | SERONO LAB (CH) | 2008-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040933-A1 | 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS | BCL2, BAX, BAD | RAD52 3656/4885MEN1 3810/4885KMT2A 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.